Replimune to Present at the Jefferies Healthcare Conference

Rhea-AI Summary

Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company, will present at the Jefferies Healthcare Conference on June 9, 2022, at 9:30 AM ET. The event will be held at Marriott Marquis in New York. Founded in 2015, Replimune focuses on innovating tumor-directed oncolytic immunotherapies using its proprietary RPx platform. This platform utilizes an HSV-1 backbone to enhance immune responses against tumors while maintaining a strong safety profile. For more details, visit www.replimune.com.

News Market Reaction – REPL

+4.39%

+4.39% Session move

In the trading session that priced this news, REPL gained 4.39%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WOBURN, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members of its management team will present in a fireside chat at the Jefferies Healthcare Conference being held at the Marriott Marquis in New York, NY on Thursday, June 9, 2022 at 9:30 AM ET.

About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform offers a unique dual, local and systemic, mechanism of action (MOA) consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment (TME) to ignite a strong and durable systemic response. This MOA is expected to be synergistic with most established and experimental cancer treatment modalities, and, with an attractive safety profile the RPx platform has the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.

Investor Inquiries
Chris Brinzey
ICR Westwicke
339.970.2843
chris.brinzey@westwicke.com

Media Inquiries
Lissette Steele
Verge Scientific Communications
202.930.4762 x 409
lsteele@vergescientific.com

FAQ

When is Replimune's presentation at the Jefferies Healthcare Conference?

Replimune's presentation is on June 9, 2022, at 9:30 AM ET.

Where is the Jefferies Healthcare Conference being held?

The conference is being held at the Marriott Marquis in New York.

What is the focus of Replimune Group's research?

Replimune focuses on developing tumor-directed oncolytic immunotherapies.

What is the RPx platform developed by Replimune?

The RPx platform is based on an HSV-1 backbone designed to enhance immunogenic cell death and systemic anti-tumor responses.

How does Replimune's RPx platform work?

It works by directly killing tumors, releasing tumor-derived antigens, and altering the tumor microenvironment to stimulate a systemic immune response.